Evidence map›Paper›PMID 38039308›Full record

Observational studyPloS one2023

Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patients.

Nora Tabea Sibert, Tobias Kurth, Clara Breidenbach, Simone Wesselmann, Günther Feick, Ernst-Günter Carl, Sebastian Dieng, Mohamad Hatem Albarghouth, Atiqullah Aziz, Stefan Baltes and 27 more

Abstract readObservational Study
In one paragraph

Observational study in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Nora Tabea SibertGerman Cancer Society (DKG), Berlin, Germany.ORCID 0000-0001-6314-8158
Tobias KurthInstitute of Public Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Clara BreidenbachGerman Cancer Society (DKG), Berlin, Germany.
Simone WesselmannGerman Cancer Society (DKG), Berlin, Germany.
Günther FeickBundesverband Prostatakrebs Selbsthilfe, Bonn, Germany.
Ernst-Günter CarlBundesverband Prostatakrebs Selbsthilfe, Bonn, Germany.
Sebastian DiengOnkoZert GmbH, Neu-Ulm, Germany.
Mohamad Hatem AlbarghouthSankt Georg Hospital, Leipzig, Germany.
Atiqullah AzizMünchen Klinik Bogenhausen, München, Germany.
Stefan BaltesKRH Klinikum Region Hannover, Klinikum Siloah-Oststadt-Heidehaus, Hannover, Germany.
Elisabeth BartolfIngolstadt Hospital, Ingolstadt, Germany.
Jens BedkeUniversity Hospital Tübingen, Tübingen, Germany.
Andreas BlanaKlinikum Fürth, Fürth, Germany.
Marko BrockRuhr-University Bochum, Marien Hospital, Herne, Germany.
Stefan ConradDIAKOVERE Friederikenstift, Hannover, Germany.
Christopher DarrUniversity Hospital Essen, Essen, Germany.
Florian DistlerKlinikum Nürnberg, Nürnberg, Germany.
Konstantinos DrososUniversity Hospital Jena, Jena, Germany.
Gregor DuweUniversity Hospital Mainz, Mainz, Germany.
Amr GaberCarl-Thiem-Klinikum, Cottbus, Germany.
Markus GiessingKliniken Maria Hilf, Mönchengladbach, Germany.
Nina Natascha HarkeMedizinische Hochschule Hannover Hospital, Hannover, Germany.
Axel HeidenreichUniversity Hospital Köln, Cologne, Germany.
Sameh HijaziKlinikum Ibbenbüren, Ibbenbüren, Germany.
Andreas HinkelFranziskus Hospital Bielefeld, Bielefeld, Germany.
Björn Theodor KaftanKlinikum Lüneburg, Lüneburg, Germany.
Shatlyk KheiderovJohanniter Krankenhaus Oberhausen, Oberhausen, Germany.
Thomas KnollKlinikum Sindelfingen-Böblingen, Sindelfingen, Germany.
Gerd LümmenGFO Kliniken Troisdorf, Troisdorf, Germany.
Inga PetersKrankenhaus Nordwest, Frankfurt am Main, Germany.
Bülent PolatUniversity Hospital Würzburg, Würzburg, Germany.
Valentin SchrodiAcademic Hospital Braunschweig, Braunschweig, Germany.
Jens-Uwe StolzenburgUniversity Clinic Leipzig, Leipzig, Germany.
Zoltan VargaSRH Kliniken Landkreis Sigmaringen, Sigmaringen, Germany.
Julius von Süßkind-SchwendiSchwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany.
Vahudin ZugorHospital Sozialstiftung Bamberg, Bamberg, Germany.
Christoph KowalskiGerman Cancer Society (DKG), Berlin, Germany.ORCID 0000-0002-7438-4321

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncontinence and sexual dysfunction are long-lasting side effects after surgical treatment (radical prostatectomy, RP) of prostate cancer (PC). For an informed treatment decision, physicians and patients should discuss expected impairments. Therefore, this paper firstly aims to develop and validate prognostic models that predict incontinence and sexual function of PC patients one year after RP and secondly to provide an online decision making tool.

methodsObservational cohorts of PC patients treated between July 2016 and March 2021 in Germany were used. Models to predict functional outcomes one year after RP measured by the EPIC-26 questionnaire were developed using lasso regression, 80-20 splitting of the data set and 10-fold cross validation. To assess performance, R2, RMSE, analysis of residuals and calibration-in-the-large were applied. Final models were externally temporally validated. Additionally, percentages of functional impairment (pad use for incontinence and firmness of erection for sexual score) per score decile were calculated to be used together with the prediction models.

resultsFor model development and internal as well as external validation, samples of 11 355 and 8 809 patients were analysed. Results from the internal validation (incontinence: R2 = 0.12, RMSE = 25.40, sexual function: R2 = 0.23, RMSE = 21.44) were comparable with those of the external validation. Residual analysis and calibration-in-the-large showed good results. The prediction tool is freely accessible: https://nora-tabea.shinyapps.io/EPIC-26-Prediction/.

conclusionThe final models showed appropriate predictive properties and can be used together with the calculated risks for specific functional impairments. Main strengths are the large study sample (> 20 000) and the inclusion of an external validation. The models incorporate meaningful and clinically available predictors ensuring an easy implementation. All predictions are displayed together with risks of frequent impairments such as pad use or erectile dysfunction such that the developed online tool provides a detailed and informative overview for clinicians as well as patients.

Indexed as

Erectile DysfunctionProstatic NeoplasmsUrinary IncontinenceHumansMalePenile ErectionProstatectomy

Identifiers

PMID38039308
PMCPMC10691723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.